Observational studyClinical rheumatology2026
Serum ferritin as a predictor of major adverse cardiovascular events in Takayasu arteritis: a two-center retrospective cohort study.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesElevated serum ferritin levels predict adverse outcomes in many autoimmune diseases. However, its clinical significance in Takayasu arteritis (TAK) is not clear. This study aimed to evaluate the predictive value of serum ferritin for major adverse cardiovascular events (MACEs) in TAK.
methodA two-center retrospective cohort study was conducted. A total of 189 treatment-naïve TAK patients who underwent serum ferritin testing at baseline were consecutively enrolled and followed longitudinally. The association between serum ferritin levels and adverse events was assessed using survival analyses.
resultsThirty-seven patients (19.6%) experienced MACEs during a median follow-up of 34.00 (20.00-55.00) months. Using the cut-off value of 68.6 μg/L, patients with high serum ferritin levels exhibited significantly higher MACE rates at 12, 36, 60, and 96 months compared to those with low levels (χ2 = 8.59, P = 0.003; χ2 = 15.23, P < 0.001; χ2 = 11.48, P < 0.001; χ2 = 12.63, P < 0.001, respectively). Serum ferritin was an independent predictor of MACEs in TAK at 96 months, both when analyzed as a continuous variable (HR: 1.003, 95% CI: 1.001-1.006, P = 0.007) and as a categorical variable (HR: 2.609, 95% CI: 1.280-5.320, P = 0.008). Furthermore, the predictive value of serum ferritin remained consistent across most subgroups, except among male patients (P for interaction = 0.018, P > 0.05), smokers (P for interaction = 0.027, P > 0.05) and patients receiving glucocorticoids (P for interaction = 0.033, P > 0.05).
conclusionsElevated serum ferritin is an independent predictor of MACEs in TAK. Patients with increased baseline serum ferritin levels should undergo close monitoring and may benefit from intensified therapeutic interventions due to their higher risk of adverse events. Key Points • Elevated Serum ferritin is associated with poorer prognosis in Takayasu arteritis. • Serum ferritin is an independent prognostic biomarker in Takayasu arteritis. • The predictive value of serum ferritin is consistent across most subgroups.
Indexed as
Identifiers
42399575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.